{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:24:16Z","timestamp":1770823456447,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.jaci.2007.05.024","type":"journal-article","created":{"date-parts":[[2007,7,13]],"date-time":"2007-07-13T07:17:52Z","timestamp":1184311072000},"page":"680-687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["KIT D816V\u2013associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities"],"prefix":"10.1016","volume":"120","author":[{"given":"Irina","family":"Maric","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Robyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Hartsell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Kirshenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B.","family":"Nutman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Noel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy D.","family":"Klion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2007.05.024_bib1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0145-2126(03)00065-1","article-title":"Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia","volume":"27","author":"Pardanani","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2007.05.024_bib2","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"suppl 3","key":"10.1016\/j.jaci.2007.05.024_bib4","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1038\/sj.thj.6200439","article-title":"FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis","volume":"5","author":"Gilliland","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.jaci.2007.05.024_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2005.05863.x","article-title":"Multilineage involvement of the fusion gene in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"132","author":"Robyn","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2007.05.024_bib6","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.20088","article-title":"Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis","volume":"77","author":"Bain","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2007.05.024_bib8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2007.05.024_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaci.2007.05.024_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jaci.2007.05.024_bib11","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2007.05.024_bib13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.leu.2403722","article-title":"Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics","volume":"19","author":"Roche-Lestienne","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2007.05.024_bib14","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2003-07-2274","article-title":"Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?","volume":"102","author":"Tefferi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V12.10.869.869","article-title":"Mast cell leukemia? malignant mastocytosis with leukemia-like manifestations","volume":"12","author":"Efrati","year":"1957","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","article-title":"Systemic mast cell disease: analysis of 58 cases and literature review","volume":"67","author":"Travis","year":"1988","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaci.2007.05.024_bib17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0002-9343(91)90214-I","article-title":"Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis","volume":"91","author":"Lawrence","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2007.05.024_bib18","series-title":"World Health Organization classification of tumours: pathology and genetics: tumours of haematopoietic and lymphoid tissues","first-page":"291","article-title":"Mastocytosis","author":"Valent","year":"2001"},{"key":"10.1016\/j.jaci.2007.05.024_bib19","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib20","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2007.05.024_bib21","first-page":"75","article-title":"Imatinib\u00a0(Gleevec)-induced hepatotoxicity","volume":"39","author":"Ayoub","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jaci.2007.05.024_bib22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2007.05.024_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2007.05.024_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2007.05.024_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2007.05.024_bib26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib27","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib28","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","article-title":"17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells","volume":"103","author":"Fumo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2007.05.024_bib30","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","article-title":"Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib31","doi-asserted-by":"crossref","first-page":"228a","DOI":"10.1182\/blood.V104.11.797.797","article-title":"BMS-354825 is a SRC\/ABL inhibitor with high nanomolar activity against the Kit D816V mutation which drives systemic mastocytosis and is imatinib-resistant","volume":"104","author":"Shah","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.05.024_bib32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0145-2126(02)00303-X","article-title":"Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease","volume":"27","author":"Pardanani","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2007.05.024_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.beha.2005.07.001","article-title":"Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system","volume":"19","author":"Tefferi","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jaci.2007.05.024_bib34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2353\/jmoldx.2006.060022","article-title":"Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology","volume":"8","author":"Akin","year":"2006","journal-title":"J Mol Diagn"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674907009906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674907009906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:10:29Z","timestamp":1758777029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674907009906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0091674907009906"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2007.05.024","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KIT D816V\u2013associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2007.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}